Veranova: A CDMO that manages complexity with confidence.
01 1Veranova, L.P.
02 1Agno Pharma Jiangsu
03 1American Pacific Corporation
04 1Apothecon Pharmaceuticals Pvt Ltd
05 1Aurobindo Pharma Limited
06 1Emcure Pharmaceuticals Limited
07 1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
08 1MSN Laboratories Private Limited
09 1NATCO PHARMA LIMITED
10 1Piramal Pharma Solutions Inc.
11 1Zhejiang ChemPacific Corporation
01 3CARMUSTINE
02 8Carmustine
01 1China
02 5India
03 5U.S.A
Veranova: A CDMO that manages complexity with confidence.
NDC Package Code : 50137-0686
Start Marketing Date : 2014-06-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/1)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 57821-002
Start Marketing Date : 2018-06-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50683-0017
Start Marketing Date : 1972-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-168
Start Marketing Date : 2024-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59981-034
Start Marketing Date : 2016-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14593-823
Start Marketing Date : 2013-04-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (130g/130g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57884-0032
Start Marketing Date : 2017-11-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (2kg/2kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0055
Start Marketing Date : 2016-12-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 70225-1107
Start Marketing Date : 2020-02-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 58621-002
Start Marketing Date : 2020-12-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (100mg/30mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
A Carmustine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carmustine, including repackagers and relabelers. The FDA regulates Carmustine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carmustine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carmustine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carmustine supplier is an individual or a company that provides Carmustine active pharmaceutical ingredient (API) or Carmustine finished formulations upon request. The Carmustine suppliers may include Carmustine API manufacturers, exporters, distributors and traders.
click here to find a list of Carmustine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carmustine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carmustine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carmustine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carmustine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carmustine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carmustine suppliers with NDC on PharmaCompass.
We have 11 companies offering Carmustine
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
